Lucio Iannone is Vice President of Venture Investments at Leaps by Bayer, the investment arm of the global life sciences company Bayer. Dr. Iannone is responsible for developing investment cases and deal execution and managing the health investment team. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science. As an investor, Lucio is also serving as board member for Mozart therapeutics, Khloris Biosciences, Immunitas Therapeutics, Deka, AffiniT and Axxam. Before joining Leaps by Bayer, he had held several senior roles in biotechnology companies and venture capital firms. He received his M.Sc in molecular biology from Cambridge university and Ph.D. in Medicine from Imperial College in London. Dr. Iannone’s expertise is in cell and gene therapy, and in several therapeutic fields such as oncology, immunology and gene therapy.